| 丙型肝炎治疗药物研发动态 |
| |
| 引用本文： | 叶海,吕田.丙型肝炎治疗药物研发动态[J].山东化工,2014(8):42-45. |
| |
| 作者姓名： | 叶海 吕田 |
| |
| 作者单位： | 南京海融医药科技有限公司,江苏南京211100 |
| |
| 摘 要： | 丙型病毒性肝炎(viral hepatitis type C,HC),系丙型肝炎病毒(HCV)感染所引起的疾病,HCV感染影响着全世界近2亿人群,是引起慢性肝脏疾病的主要病因,进一步会引起肝硬化、肝癌和肝功能衰竭。本文主要介绍HCV及其结构、基于不同靶点的治疗丙肝的药物(标准方案、DAA药物、DAA药物联合标准方案、DAA药物相联合、其他药物联合、HCV疫苗等)的最新研发动态,并对目前的研发现状进行了展望。
|
| 关 键 词： | 丙型肝炎病毒 治疗丙肝的药物 DAA药物 研发动态 |
Hepatitis C and the Latest Development Dynamic of Its Drugs |
| |
| Affiliation: | Ye Hai, Lyu Tian (Nanjing Heron Pharmaceutical Co. ,Ltd. , Nanjing 211100,China) |
| |
| Abstract: | Viral hepatitis C （viral hepatitis type C, HC）, is caused by the hepatitis C vires （HCV） , HCV infection affects nearly 200 million people around the world, is the main cause of chronic liver disease, further cause liver cirrhosis, liver cancer and liver failure. Here , this paper introduced the HCV situation and its structure , the latest research and development of dynamic of drags based on different targets for the treatment of hepatitis e （ standard solution, DAA drugs, DAA drugs combined standard solution, DAA phase joint, other drags combined, HCV vaccine, etc. ） , and the present situation of the current research and development is discussed here. |
| |
| Keywords: | hepatitis C virus treatment of hepatitis c drugs DAA durgs research and development dynamic |
| 本文献已被 CNKI 维普 等数据库收录！ |
|
